ReviewJournal of cellular and molecular medicine2008
IL-24: a classic cytokine and/or a potential cure for cancer?
Review in Journal of cellular and molecular medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- The Combinatorial Effect of Ad-IL-24 and Ad-HSV-tk/GCV on Tumor Size, Autophagy, and UPR Mechanisms in Multiple Myeloma Mouse Model.Biochemical genetics · 2025Article
- Interleukin-22 receptor 1-mediated stimulation of T-type CaCell communication and signaling : CCS · 2024Article
- Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research.Cancers · 2023Review
- Oncolytic viruses for triple negative breast cancer and beyond.Biomarker research · 2021Review
- Targeting IL-10 Family Cytokines for the Treatment of Human Diseases.Cold Spring Harbor perspectives in biology · 2019Review
- Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer.Molecular cancer · 2018Review
- Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?Oncoimmunology · 2015Article
- The IL-20 subfamily of cytokines--from host defence to tissue homeostasis.Nature reviews. Immunology · 2014Review
- Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells.Cell communication and signaling : CCS · 2012Article
- A new oncolytic adenoviral vector carrying dual tumour suppressor genes shows potent anti-tumour effect.Journal of cellular and molecular medicine · 2012Article
- Molecular Mechanisms Governing IL-24 Gene Expression.Immune network · 2012Article
- Recombinant adenovirus IL-24-Bax promotes apoptosis of hepatocellular carcinoma cells in vitro and in vivo.Cancer gene therapy · 2010Article
- Structure and function of interleukin-22 and other members of the interleukin-10 family.Cellular and molecular life sciences : CMLS · 2010Review
- Structural mapping of post-translational modifications in human interleukin-24: role of N-linked glycosylation and disulfide bonds in secretion and activity.The Journal of biological chemistry · 2009Article
- Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case--control study.Genes and immunity · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-24, a member of the IL-10 family of cytokines, is produced by monocytes and Th2 cells. Interestingly, immune cells do not appear to express specific IL-24 receptor chains (IL-20R1/IL-20R2 and IL-22R/IL-20R2), it is therefore unlikely that IL-24 has classical immune-modulating properties. Skin, on the other hand, seems to represent a major target tissue for IL-24 and related cytokines such as IL-19, -20, and -22. However, the initial interest in IL-24 did not arise from its physiological signalling properties through its cognate receptors but rather because of its tentative ability to selectively kill different cancer cells. In an attempt to further investigate the signalling events underlying the IL-24-induced cancer cell death, we found that melanoma cell lines did not react in the expected and previously described way. Using several different forms and delivery modes of IL-24, we were unable to detect any apoptosis-inducing properties of this cytokine in melanoma cells. In the present 'Point of view' we will briefly summarize these findings and put them in context of published reports stating that IL-24 might be a long sought after treatment for several types of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.